

Original Article

Primary Ciliary Dyskinesia in Taif, Saudi Arabia: A Retrospective Study

Abdullah Khayat¹, Abdullah Thomali², Anas Assiri², Mohammad Qurashi²

¹Pediatric Pulmonology, Faculty of Medicine, Taif university, Taif, Saudi Arabia.

²College of Medicine, Taif University, Taif, Saudi Arabia.

Correspondence should be addressed to Abdullah Khayat; Pediatric Pulmonology, Faculty of Medicine, Taif university, Taif, Saudi Arabia. Email: dr_amnk@yahoo.com

Received: 16 July 2021, Revised: 23 July 2021, Accepted: 23 July 2021, Published: 10 August 2021

Copyright © 2021 Khayat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction: Primary ciliary dyskinesia, also known as immotile-cilia syndrome, is a rare genetic disease that is inherited in an autosomal recessive manner, unfortunately there are no studies for primary ciliary dyskinesia in Taif region, yet much is still lacking in terms of identifying the different characteristics of this disease. In this paper, we aim to briefly cover those studies published about primary ciliary dyskinesia in Taif region, as well as to provide recommendations and guidelines for future studies.

Methods: This is a retrospective chart review study that was conducted by reviewing the case records of children attending primary care in one of the children's hospitals in Taif city. Children diagnosed with bronchiectasis with primary ciliary dyskinesia were included in the study. Children with other respiratory diseases were excluded from the study. The bronchiectasis diagnosis was made using a high-resolution chest computed tomography scan.

Results: A total of 10 patients were included in the study with a mean age of 4.3 ± 2.9 years. Gender had even distribution with five males and five females. It was observed that six patients had bronchopulmonary manifestations in which five patients showed asthma and one patient had pneumopathies. The bronchopulmonary manifestations were comparatively observed more in female patients (50%) where only one of the male patients had such manifestations ($p=0.010$).

Conclusion: Rhinosinusitis is found to be a major clinical manifestation in primary ciliary dyskinesia patients and the prevalence of other bronchopulmonary manifestations. The management of primary ciliary dyskinesia has become challenging and in future primary ciliary dyskinesia studies in diagnosis management should utilize more collaborative partnerships between different healthcare disciplines.

Keywords: primary ciliary dyskinesia, immotile-cilia syndrome, kartagener syndrome, taif

Introduction

Bronchiectasis is a chronic progressive lung disease affecting the airways, and it still remains one of the most neglected respiratory diseases among children (1). Epidemiological data show that the incidence of bronchiectasis has increased over the past years, and this may create a substantial healthcare burden on the parents and health sector (2). Some of the causes of bronchiectasis include Cystic fibrosis, Allergic bronchopulmonary aspergillosis, Alpha1-antitrypsin deficiency, Primary ciliary dyskinesia (PCD), Autoimmune/connective tissue diseases (rheumatoid arthritis, Systemic Lupus Erythematosus), Aspiration, Inflammatory bowel diseases, Congenital malformations such as Williams–Campbell syndrome (bronchomalacia), Mounier-Kuhn syndrome (tracheobronchomegaly) and lung sequestration, Humoral immunodeficiency and postinfectious (pneumonia, Bordetella pertussis, Mycobacterium tuberculosis, nontuberculous mycobacteria) (3-8). Among these causes, Primary Ciliary Dyskinesia (PCD) is one of the main causes of bronchiectasis, a rare genetic disorder with an autosomal recessive trait that causes defects in the cilia structure leading to dysfunction in the mucociliary clearance (9).

The mean incidence of PCD in bronchiectasis cases varies from 2.0-10.3%, and the estimated overall incidence is reported to be 1 per 10,000–20,000 births (10, 11). The inadequacy in the diagnostic methods used often makes it difficult to estimate the prevalence of PCD (12). In patients with PCD, the cilia cells lining in the nasopharynx, middle ear, paranasal sinuses, the lower respiratory tract, and the reproductive tract are disordered and dysfunctional, leading to its clinical manifestations. In children with PCD, symptoms often appear at birth or after some weeks, which is characterized by respiratory distress, abnormalities in chest x-ray, atelectasis in particular, and hypoxia (13, 14). In a newborn child, Continuous rhinorrhea, respiratory distress, or neonatal pneumonia could increase the suspicion of the presence of PCD (13), whereas, in childhood, the symptoms often include chronic productive cough, atypical asthma unresponsive to treatment, rhinosinusitis, idiopathic, bronchiectasis and recurrent otitis (15). The clinical phenotype of PCD is very wide irrespective of any age, and in children, it is often challenging to recognize respiratory exacerbations even when they have a persistent wet cough. In healthy children, most of the symptoms or signs of respiratory diseases are very common, and this makes the diagnosis of PCD often

difficult, which is usually made beyond infancy or childhood that may delay the start of appropriate treatment (16, 17). The main respiratory manifestation in PCD patients usually consists of recurrent to chronic upper and lower respiratory tract infections that often get complicated with bronchiectasis as they get older (18). It is reasonable to assume that the prevalence of bronchiectasis due to PCD might be variable and local data would be required to define national health policy priorities in Saudi Arabia. So far, no epidemiological data have been conducted in the Taif region in inpatient and outpatient hospital settings. In addition, the co-existence of bronchiectasis with other obstructive pulmonary diseases, such as asthma and other pulmonary diseases, might hinder the precise assessment of bronchiectasis epidemiology; by now, no studies have evaluated prevalence and incidence in a population of patients with only bronchiectasis and no concomitant diagnosis of other chronic respiratory diseases. This study aims to estimate the prevalence and causes of bronchiectasis due to PCD in the Taif region in the children followed up by primary care physicians.

Methodology

This is a retrospective chart review study that was conducted by reviewing the case records of children attending primary care in Children’s Hospital at Taif, Saudi Arabia. Children diagnosed with bronchiectasis with PCD were included in the study. Children with other respiratory diseases were excluded from the study. The bronchiectasis diagnosis was made using a high-resolution chest computed tomography (CT) scan. A convenience sampling method was used to collect the data based on the availability during the study period (October 2020- March 2021). A standardized proforma was used to collect the information from the case records, which recorded the children's age, gender, and data on conditions associated with bronchiectasis, including bronchopulmonary manifestations, ENT events, presence of complete situs inversus and Incomplete situs inversus, dextrocardia, Urogenital events, sensory impairment, and Family history respiratory disorders. All the collected information was tabulated on a Microsoft Excel sheet and transferred to IBM Statistical Package for Social Sciences, Version 23 (SPSS Inc., Chicago, IL, USA) for analysis. Descriptive statistics in the form of frequencies and percentages using suitable tables and figures were used to represent categorical data.

Results

In this hospital based retrospective study we included 10 children who attended the hospital due to bronchiectasis with PCD. The mean age of the patients was found to be 4.3 ± 2.9 years and the gender distribution showed that 50% (n=5) were males and 50% (n=5) were females. It was observed that 60% (n=6) had bronchopulmonary manifestations in which five patients showed asthma and one patient had pnuemopathies.




Figure 1. Bronchopulmonary manifestation (n=10)

The bronchopulmonary manifestations were comparatively more observed in female patients (50%) where only one of the male patients had such manifestations (p=0.010) (Table 1, Figure 1).

The prevalence of Rhinosinusitis was found in 50% (n=5) of the patients, which didn't show any statistically significant association with gender of the patients (p=0.527). The prevalence of other ENT events showed that 3 patients had history of Neonatal respiratory distress syndrome (neonatal RDS) and one patient had polydactyly. Out of 10 patients one male patient had shown Complete situs inversus and there were no incomplete situs inversus reported. Dextrocardia was present in one male patient and two male patients showed urogenital events, which was mild hydronephrosis and polycystic kidney (p=0.114). When we assessed the family history of any respiratory or ENT events in child's parents it was found that three patients reported Rhinosinusitis and one patient had Asthma (Table 1).

Table 1: Causes and events based on gender of the patient and their relation

			Gender		Total	P-value
			Female	Male		
Bronchopulmonary manifestations	Present	N	5	1	6	0.010*
		%	83.3%	16.7%	60.0%	
	Absent	N	0	4	4	
		%	0.0%	100.0%	40.0%	
Rhinosinusitis	Present	N	2	3	5	0.527
		%	40.0%	60.0%	50.0%	
	Absent	N	3	2	5	
		%	60.0%	40.0%	50.0%	
Other ENT Events	Present	N	2	2	4	1.000
		%	50.0%	50.0%	40.0%	
	Absent	N	3	3	6	
		%	50.0%	50.0%	60.0%	
Complete situs inversus	Present	N	0	1	1	0.292
		%	0.0%	100.0%	10.0%	
	Absent	N	5	4	9	
		%	55.6%	44.4%	90.0%	
Incomplete situs inversus	Present	N	0	0	0	--
		%	0.0%	0.0%	0.0%	
	Absent	N	5	5	10	
		%	50.0%	50.0%	100.0%	
Dextrocardia	Present	N	0	1	1	0.292
		%	0.0%	100.0%	10.0%	
	Absent	N	5	4	9	
		%	55.6%	44.4%	90.0%	
Urogenital events	Present	N	0	2	2	0.114
		%	0.0%	100.0%	20.0%	
	Absent	N	5	3	8	
		%	62.5%	37.5%	80.0%	
Family history of Respiratory/ENT disorders	Present	N	1	3	4	0.197
		%	25.0%	75.0%	40.0%	
	Absent	N	4	2	6	
		%	66.7%	33.3%	60.0%	

ENT: ears nose and throat, N: numbers, * Statistically significant

Discussion

In infants with PCD, the abnormal ciliary function could gradually lead to respiratory distress, which leads to persistent wet cough, rhinosinusitis, and bronchiectasis (18). In our study, half of the patients had rhinosinusitis, and this may lead to stasis and bacterial colonization that commonly include bacteria such *Streptococcus pneumoniae*, *Moraxella catarrhalis*, *Haemophilus influenzae non-type b*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* (19). Genetic studies show that more than 35 cilia-related genes have proven to cause PCD, and experts have the opinion that there are more genes to be discovered for this disorder (20, 21). Thus, minimizing exposure to these respiratory infections and pathogens is crucial in these children when visiting hospitals, schools, or daycare settings. When monitoring PCD in children, the clinical outcomes should give the physician or pediatrician an insight into the patient's current status compared with the previous assessment of the disease's status. The clinician could look into various clinical outcomes such as mortality, exacerbation rate, admission rates in hospitals, growth outcomes (anthropometric measurements of the child, bioelectrical impedance analysis), lung function (Lung Clearance Index, plethysmography, Spirometry), and using age-appropriate questionnaires such as QOL-PCD (22-24).

The current study findings show that only one patient had chronic situs inversus. It is often said that patients having these situs abnormalities have Kartagener syndrome, a triad of chronic sinusitis dextrocardia with situs inversus and bronchiectasis (25). In our study, dextrocardia was present in one patient, and the same patient had chronic sinusitis, which suggests that the patient may have Kartagener syndrome. Chronic obstructive pulmonary disease (COPD) is considered a co-morbidity in patients with bronchiectasis, which is often associated with marked bronchial inflammation, frequent pathogenic colonization, and severe airway obstruction (26).

The diagnosis of PCD is often a complex and challenging process due to its clinical and genetic heterogeneity. The diagnosis is often confirmed by transmission electron microscopy (TEM) for a classic PCD ultra-structural ciliary defect or biallelic mutations in an already identified PCD gene, which again depends on age criteria (27, 28). In the management of PCD, the main aim should be to recover or maintain lung function, which depends on mucus clearance, respiratory infection prevention, and effective antibiotic therapy for bacterial infections (29).

The management is usually symptomatic and depends on specific conditions associated with PCD. In PCD patients, Otitis Media with Effusion (OME) is a universal finding, and the management of OME is often controversial. Studies have demonstrated that ventilation tube insertion is effective in improving hearing and achieving a dry ear (30, 31). But recent evidence shows that ventilation tubes offer no advantages and could lead to persistent mucous discharge and also could predispose to chronic otorrhea (16). In PCD patients, chronic sinusitis symptoms are lifelong, and it is the focal point of all respiratory infections. Long-term combinational therapy of antibiotics and steroid nasal sprays could control sinusitis in most PCD cases (32, 33). Even though maintenance therapy using antibiotics has shown clinical effectiveness, it could lead to antibiotic resistance development. Another common finding in PCD patients is Nasal polyposis, and the prevalence of approximately 30% has been reported (34). This condition's treatment involves a combination of medical therapy using corticosteroids and surgical measures after patient assessment (34, 35). In patients with bronchiectasis, antibiotic therapy depending upon the isolated organisms could give symptomatic relief. In some patients, a lobectomy is a therapeutic option; some experts have the opinion that it is rarely needed due to the reasons that the basal defective mechanism is diffuse and is not limited to lobes of the lungs (36). Our study poses some limitations. Firstly, the sample size we included was insufficient for drawing enough conclusions for the prevalence of many risk factors. Secondly, this research was conducted in a single center may have called for bias. A multi-center study involving more patients with PCD is further needed to verify the current findings.

Conclusion

In conclusion, Rhinosinusitis is found to be a major clinical manifestation in PCD patients and the prevalence of other bronchopulmonary manifestations such as asthma and pneumopathies are not uncommon in PCD patients. The diagnosis and management of PCD in bronchiectasis in patients depends on the clinical presentation and associated comorbidities. Due to the lack clinical trials, the management of PCD has become challenging and in future PCD studies in diagnosis management should utilize more collaborative partnerships between different disciplinarians and countries.

Declaration**Statement:**

The authors declare no conflict of interest.

Funding:

None

Ethical Consideration:

The study was approved by Taif University Institutional Review Board (IRB) and all data was collected assuring complete confidentiality of the patient's personal information. All methods were performed in accordance with the relevant guidelines and regulations Declaration of Helsinki.

Data Availability:

All data is available withing the article.

References

1. Ho T, Cusack RP, Chaudhary N, Satia I, Kurmi OP. Under- and over-diagnosis of COPD: a global perspective. *Breathe* (Sheffield, England). 2019;15(1):24-35.
2. Goeminne PC, Hernandez F, Diel R, Filonenko A, Hughes R, Juelich F, et al. The economic burden of bronchiectasis – known and unknown: a systematic review. *BMC Pulmonary Medicine*. 2019;19(1):54.
3. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. *American journal of respiratory and critical care medicine*. 2000;162(4 Pt 1):1277-84.
4. McShane PJ, Naureckas ET, Tino G, Streck ME. Non-cystic fibrosis bronchiectasis. *American journal of respiratory and critical care medicine*. 2013;188(6):647-56.
5. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. *Respiratory medicine*. 2007;101(6):1163-70.
6. Anwar GA, McDonnell MJ, Worthy SA, Bourke SC, Afolabi G, Lordan J, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. *Respiratory medicine*. 2013;107(7):1001-7.
7. Qi Q, Wang W, Li T, Zhang Y, Li Y. Aetiology and clinical characteristics of patients with bronchiectasis in a Chinese Han population: A prospective study. *Respirology* (Carlton, Vic). 2015;20(6):917-24.
8. Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. *Annals of the American Thoracic Society*. 2015;12(12):1764-70.
9. Noone PG, Leigh MW, Sannuti A, Minnix SL, Carson JL, Hazucha M, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. *American journal of respiratory and critical care medicine*. 2004;169(4):459-67.
10. Smith MP. Diagnosis and management of bronchiectasis. *Canadian Medical Association Journal*. 2017;189(24):E828.
11. Mirra V, Werner C, Santamaria F. Primary Ciliary Dyskinesia: An Update on Clinical Aspects, Genetics, Diagnosis, and Future Treatment Strategies. *Frontiers in pediatrics*. 2017;5:135.
12. Leigh MW, O'Callaghan C, Knowles MR. The challenges of diagnosing primary ciliary dyskinesia. *Proc Am Thorac Soc*. 2011;8(5):434-7.
13. Ferkol T, Leigh M. Primary ciliary dyskinesia and newborn respiratory distress. *Seminars in perinatology*. 2006;30(6):335-40.
14. Sagel SD, Davis SD, Campisi P, Dell SD. Update of respiratory tract disease in children with primary ciliary dyskinesia. *Proc Am Thorac Soc*. 2011;8(5):438-43.
15. Lobo J, Zariwala MA, Noone PG. Primary ciliary dyskinesia. *Seminars in respiratory and critical care medicine*. 2015;36(2):169-79.
16. Coren ME, Meeks M, Morrison I, Buchdahl RM, Bush A. Primary ciliary dyskinesia: age at diagnosis and symptom history. *Acta paediatrica* (Oslo, Norway : 1992). 2002;91(6):667-9.
17. Sommer JU, Schäfer K, Omran H, Olbrich H, Wallmeier J, Blum A, et al. ENT manifestations in patients with primary ciliary dyskinesia: prevalence and significance of otorhinolaryngologic co-morbidities. *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery*. 2011;268(3):383-8.

18. Lucas JS, Gahleitner F, Amorim A, Boon M, Brown P, Constant C, et al. Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials. *ERJ Open Res.* 2019;5(1):00147-2018.
19. Acosta R. Rhinosinusitis. *Pediatric Emergency Medicine.* 2008;405-8.
20. Lucas JS, Barbato A, Collins SA, Goutaki M, Behan L, Caudri D, et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. *European Respiratory Journal.* 2017;49(1).
21. Horani A, Ferkol TW, Dutcher SK, Brody SL. Genetics and biology of primary ciliary dyskinesia. *Paediatric respiratory reviews.* 2016;18:18-24.
22. Behan L, Rubbo B, Lucas JS, Dunn Galvin A. The patient's experience of primary ciliary dyskinesia: a systematic review. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.* 2017;26(9):2265-85.
23. Knowles MR, Daniels LA, Davis SD, Zariwala MA, Leigh MW. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. *American journal of respiratory and critical care medicine.* 2013;188(8):913-22.
24. Lucas JS, Behan L, Dunn Galvin A, Alpern A, Morris AM, Carroll MP, et al. A quality-of-life measure for adults with primary ciliary dyskinesia: QOL-PCD. *The European respiratory journal.* 2015;46(2):375-83.
25. Knowles MR, Zariwala M, Leigh M. Primary Ciliary Dyskinesia. *Clinics in chest medicine.* 2016;37(3):449-61.
26. Martínez-García M, Soler-Cataluña JJ, Donat Sanz Y, Catalán Serra P, Agramunt Lerma M, Ballestín Vicente J, et al. Factors associated with bronchiectasis in patients with COPD. *Chest.* 2011;140(5):1130-7.
27. Shapiro AJ, Zariwala MA, Ferkol T, Davis SD, Sagel SD, Dell SD, et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. *Pediatric pulmonology.* 2016;51(2):115-32.
28. Lucas JS, Leigh MW. Diagnosis of primary ciliary dyskinesia: searching for a gold standard. *Eur Respiratory Soc;* 2014.
29. Yoo Y, Koh YY. Current treatment for primary ciliary dyskinesia conditions. *Expert opinion on pharmacotherapy.* 2004;5(2):369-77.
30. Jahrsdoerfer R, Feldman PS, Rubel EW, Guerrant JL, Eggleston PA, Selden RF. Otitis media and the immotile cilia syndrome. *The Laryngoscope.* 1979;89(5 Pt 1):769-78.
31. Campbell RG, Birman CS, Morgan L. Management of otitis media with effusion in children with primary ciliary dyskinesia: a literature review. *International journal of pediatric otorhinolaryngology.* 2009;73(12):1630-8.
32. Chee L, Graham SM, Carothers DG, Ballas ZK. Immune dysfunction in refractory sinusitis in a tertiary care setting. *The Laryngoscope.* 2001;111(2):233-5.
33. Cornet ME, Georgalas C, Reinartz SM, Fokkens WJ. Long-term results of functional endoscopic sinus surgery in children with chronic rhinosinusitis with nasal polyps. *Rhinology.* 2013;51(4):328-34.
34. Schidlow DV. Primary ciliary dyskinesia (the immotile cilia syndrome). *Annals of allergy.* 1994;73(6):457-68; quiz 68-70.
35. Lund VJ. Diagnosis and treatment of nasal polyps. *BMJ.* 1995;311(7017):1411-4.
36. Pedersen M, Stafanger G. Bronchopulmonary symptoms in primary ciliary dyskinesia. A clinical study of 27 patients. *European journal of respiratory diseases Supplement.* 1983;127:118-28.